{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:26:19Z","timestamp":1791188779416,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Early Human Development"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.earlhumdev.2011.05.009","type":"journal-article","created":{"date-parts":[[2011,6,27]],"date-time":"2011-06-27T13:46:01Z","timestamp":1309182361000},"page":"683-690","source":"Crossref","is-referenced-by-count":24,"title":["Mediators involved in retinopathy of prematurity and emerging therapeutic targets"],"prefix":"10.1016","volume":"87","author":[{"given":"A.","family":"Mataftsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Dimitrakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.G.W.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0005","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1542\/peds.2004-1180","article-title":"Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs","volume":"115","author":"Gilbert","year":"2005","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.05.009_bb0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity","volume":"10","author":"Chen","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.earlhumdev.2007.11.008","article-title":"Pathogenesis of retinopathy of prematurity and possible preventive strategies","volume":"84","author":"Fleck","year":"2008","journal-title":"Early Hum Dev"},{"issue":"15","key":"10.1016\/j.earlhumdev.2011.05.009_bb0020","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1073\/pnas.0813061106","article-title":"VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"10.1016\/j.earlhumdev.2011.05.009_bb0025","doi-asserted-by":"crossref","first-page":"7822","DOI":"10.1158\/0008-5472.CAN-04-0934","article-title":"VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression","volume":"64","author":"Woolard","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.earlhumdev.2011.05.009_bb0030","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1167\/iovs.09-4296","article-title":"VEGF-A165b is cytoprotective and anti-angiogenic in the retina","volume":"51","author":"Magnussen","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5\u20136","key":"10.1016\/j.earlhumdev.2011.05.009_bb0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1440-1827.2002.01367.x","article-title":"Pathological significance of vascular endothelial growth factor A isoform expression in human cancer","volume":"52","author":"Nakamura","year":"2002","journal-title":"Pathol Int"},{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0040","doi-asserted-by":"crossref","unstructured":"Yuan A, Lin CY, Chou CH, Shih CM, Chen CY, Cheng HW et al. Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS One. 2011 Jan 20;6(1):e16062.","DOI":"10.1371\/journal.pone.0016062"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.05.009_bb0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ceb.2008.12.012","article-title":"VEGFs and receptors involved in angiogenesis versus lymphangiogenesis","volume":"21","author":"Lohela","year":"2009","journal-title":"Curr Opin Cell Biol"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.05.009_bb0050","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12041-009-0068-0","article-title":"Mediators of ocular angiogenesis","volume":"88","author":"Qazi","year":"2009","journal-title":"J Genet"},{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0055","doi-asserted-by":"crossref","unstructured":"Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer. 2008 Nov;8(11):880-7.","DOI":"10.1038\/nrc2505"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.05.009_bb0060","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog Retin Eye Res"},{"issue":"Pt 20","key":"10.1016\/j.earlhumdev.2011.05.009_bb0065","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1242\/jcs.016410","article-title":"Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors","volume":"121","author":"Nowak","year":"2008","journal-title":"J Cell Sci"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0070","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.survophthal.2009.02.004","article-title":"Bevacizumab (Avastin) for the treatment of ocular disease","volume":"54","author":"Gunther","year":"2009","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0075","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/ICU.0b013e32832d25b3","article-title":"Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration","volume":"20","author":"Ciulla","year":"2009","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0080","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"3","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0301-4738.29505","article-title":"Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity","volume":"55","author":"Shah","year":"2007","journal-title":"Indian J Ophthalmol"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.05.009_bb0090","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.earlhumdev.2011.05.009_bb0095","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.05.009_bb0100","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.05.009_bb0105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"issue":"Suppl. 3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0110","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"issue":"Suppl. 3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0115","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","article-title":"Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"14","author":"Law","year":"2010","journal-title":"J AAPOS"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.05.009_bb0125","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1203\/PDR.0b013e31819d9e8c","article-title":"A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants","volume":"65","author":"L\u00f6fqvist","year":"2009","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.05.009_bb0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/jc.2008-1293","article-title":"Fresh-frozen plasma as a source of exogenous insulin-like growth factor-I in the extremely preterm infant","volume":"94","author":"Hansen-Pupp","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0135","first-page":"CD004865","article-title":"Early versus late erythropoietin for preventing red blood cell transfusion in preterm and\/or low birth weight infants","volume":"3","author":"Aher","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0140","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaapos.2007.08.009","article-title":"Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model","volume":"12","author":"Suk","year":"2008","journal-title":"J AAPOS"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.05.009_bb0145","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00417-009-1248-6","article-title":"The influence of gestational age on the dynamic behavior of other risk factors associated with retinopathy of prematurity (ROP)","volume":"248","author":"Fortes Filho","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.05.009_bb0150","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1592\/phco.28.11.1335","article-title":"Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low-birth-weight infants","volume":"28","author":"Schneider","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1055\/s-0029-1224872","article-title":"The effect of recombinant human erythropoietin on the development of retinopathy of prematurity","volume":"27","author":"Shah","year":"2010","journal-title":"Am J Perinatol"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.05.009_bb0160","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jaapos.2009.07.007","article-title":"Effect of granulocyte colony-stimulating factor on the incidence of threshold retinopathy of prematurity","volume":"13","author":"Bhola","year":"2009","journal-title":"J AAPOS"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.05.009_bb0165","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0022-3476(97)70031-3","article-title":"Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials","volume":"131","author":"Raju","year":"1997","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.earlhumdev.2011.05.009_bb0170","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","article-title":"Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels","volume":"248","author":"Lee","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"Suppl. 4","key":"10.1016\/j.earlhumdev.2011.05.009_bb0175","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/IAE.0b013e3181ca1457","article-title":"Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin)","volume":"30","author":"Dorta","year":"2010","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.earlhumdev.2011.05.009_bb0180","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"BEAT-ROP cooperative group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.earlhumdev.2011.05.009_bb0185","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1158\/0008-5472.CAN-07-6577","article-title":"Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity","volume":"15;68","author":"Kawamura","year":"2008","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.earlhumdev.2011.05.009_bb0190","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1167\/iovs.09-4360","article-title":"Recombinant human VEGF165b inhibits experimental choroidal neovascularisation","volume":"51","author":"Hua","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0195","first-page":"108","article-title":"Vascular endothelial growth factor receptor-2 in breast cancer","volume":"1806","author":"Guo","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0200","first-page":"1965","article-title":"Inhibition of retinal neovascularization by siRNA targeting VEGF(165)","volume":"14","author":"Xia","year":"2008","journal-title":"Mol Vis"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.05.009_bb0205","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.coph.2009.07.006","article-title":"Aptamers: a new class of oligonucleotides in the drug discovery pipeline?","volume":"9","author":"Dausse","year":"2009","journal-title":"Curr Opin Pharmacol"},{"issue":"16","key":"10.1016\/j.earlhumdev.2011.05.009_bb0210","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2009-01-197095","article-title":"AlphaB-crystallin regulation of angiogenesis by modulation of VEGF","volume":"115","author":"Kase","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.05.009_bb0215","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1021\/jm1002167","article-title":"Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist","volume":"53","author":"Gautier","year":"2010","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.05.009_bb0220","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1073\/pnas.0915141107","article-title":"From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway","volume":"107","author":"Giordano","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0225","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-1-4419-1399-9_39","article-title":"Protamine sulfate downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF and its receptor binding in vitro","volume":"664","author":"Hu","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0230","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.exer.2009.09.022","article-title":"Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1\/2 and Akt","volume":"90","author":"Nakamura","year":"2010","journal-title":"Exp Eye Res"},{"issue":"21","key":"10.1016\/j.earlhumdev.2011.05.009_bb0235","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1073\/pnas.0902659106","article-title":"Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression","volume":"106","author":"Guma","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.earlhumdev.2011.05.009_bb0240","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2010-02-271478","article-title":"PLD1-dependent PKC{gamma} activation downstream to Src is essential for the development of pathological retinal neovascularization","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.05.009_bb0245","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.ophtha.2009.04.026","article-title":"Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.earlhumdev.2011.05.009_bb0250","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1073\/pnas.101113998","article-title":"Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity","volume":"98","author":"Hellstrom","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.earlhumdev.2011.05.009_bb0255","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/archopht.124.12.1711","article-title":"Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity","volume":"124","author":"L\u00f6fqvist","year":"2006","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0260","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbrc.2009.08.114","article-title":"Role of insulin-like growth factor-1 (IGF-1) in regulating cell cycle progression","volume":"389","author":"Ma","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.05.009_bb0265","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/er.2008-0028","article-title":"Unraveling insulin-like growth factor binding protein-3 actions in human disease","volume":"30","author":"Jogie-Brahim","year":"2009","journal-title":"Endocr Rev"},{"issue":"9","key":"10.1016\/j.earlhumdev.2011.05.009_bb0270","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCRESAHA.109.199059","article-title":"Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation","volume":"105","author":"Kielczewski","year":"2009","journal-title":"Circ Res"},{"issue":"25","key":"10.1016\/j.earlhumdev.2011.05.009_bb0275","doi-asserted-by":"crossref","first-page":"10589","DOI":"10.1073\/pnas.0702031104","article-title":"IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth","volume":"104","author":"L\u00f6fqvist","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.earlhumdev.2011.05.009_bb0280","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1056\/NEJMoa041773","article-title":"Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy","volume":"353","author":"Watanabe","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.05.009_bb0285","first-page":"526","article-title":"Erythropoietin deficiency decreases vascular stability in mice","volume":"118","author":"Chen","year":"2008","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.05.009_bb0290","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.exer.2010.03.005","article-title":"Pigment epithelium-derived factor inhibits erythropoietin-induced retinal endothelial cell angiogenesis by suppression of PI3K\/Akt pathway","volume":"90","author":"Haribalaganesh","year":"2010","journal-title":"Exp Eye Res"},{"issue":"9","key":"10.1016\/j.earlhumdev.2011.05.009_bb0295","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ophtha.2008.12.023","article-title":"Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0300","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1167\/iovs.08-2521","article-title":"Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy","volume":"50","author":"Chen","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.05.009_bb0305","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000215825","article-title":"Suppression of retinal neovascularization by small-interference RNA targeting erythropoietin","volume":"223","author":"Xiong","year":"2009","journal-title":"Ophthalmologica"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.05.009_bb0310","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood.V78.11.2791.bloodjournal78112791","article-title":"Granulocyte colony-stimulating factor and its receptor","volume":"78","author":"Demetri","year":"1991","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.earlhumdev.2011.05.009_bb0315","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/j.1538-7836.2010.03900.x","article-title":"Granulocyte colony-stimulating factor (G-CSF) depresses angiogenesis in vivo and in vitro: implications for sourcing cells for vascular regeneration therapy","volume":"8","author":"Tura","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.earlhumdev.2011.05.009_bb0320","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"issue":"27","key":"10.1016\/j.earlhumdev.2011.05.009_bb0325","doi-asserted-by":"crossref","first-page":"12216","DOI":"10.1073\/pnas.1004143107","article-title":"PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets","volume":"107","author":"Hou","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"10.1016\/j.earlhumdev.2011.05.009_bb0330","doi-asserted-by":"crossref","first-page":"15500","DOI":"10.1074\/jbc.M110.113787","article-title":"Platelet-derived growth factor-DD targeting arrests pathological angiogenesis by modulating glycogen synthase kinase-3beta phosphorylation","volume":"285","author":"Kumar","year":"2010","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0335","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/156652410791065336","article-title":"PEDF in angiogenic eye diseases","volume":"10","author":"Tombran-Tink","year":"2010","journal-title":"Curr Mol Med"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0340","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1167\/iovs.09-4455","article-title":"Effects of human recombinant PEDF protein and PEDF-derived peptide 34-mer on choroidal neovascularization","volume":"51","author":"Amaral","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.earlhumdev.2011.05.009_bb0345","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1096\/fj.06-7359com","article-title":"The SDF-1\/CXCR4 ligand\/receptor pair is an important contributor to several types of ocular neovascularization","volume":"21","author":"Lima e Silva","year":"2007","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0350","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/glia.20900","article-title":"Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy","volume":"58","author":"Dorrell","year":"2010","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0355","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cardiores.2004.10.036","article-title":"TGF-beta receptor function in the endothelium","volume":"65","author":"Lebrin","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0360","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrm2262","article-title":"Extracellular control of TGFbeta signalling in vascular development and disease","author":"Ten Dijke","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0365","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/jcp.22296","article-title":"Agents that bind annexin A2 suppress ocular neovascularization","volume":"225","author":"Lima e Silva","year":"2010","journal-title":"J Cell Physiol"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.05.009_bb0370","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1167\/iovs.09-4472","article-title":"Expression, localization, and functional coupling of the somatostatin receptor subtype 2 in a mouse model of oxygen-induced retinopathy","volume":"51","author":"Dal Monte","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.05.009_bb0375","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1182\/blood-2007-08-109710","article-title":"Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice","volume":"111","author":"Chrzanowska-Wodnicka","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.earlhumdev.2011.05.009_bb0380","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/02713680701553052","article-title":"Modulation of hypoxia-induced neovascularization by JSM6427, an integrin alpha5beta1 inhibiting molecule","volume":"32","author":"Maier","year":"2007","journal-title":"Curr Eye Res"},{"issue":"8","key":"10.1016\/j.earlhumdev.2011.05.009_bb0385","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1167\/iovs.08-2607","article-title":"A peptide derived from type 1 thrombospondin repeat-containing protein WISP-1 inhibits corneal and choroidal neovascularization","volume":"50","author":"Cano Mdel","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0390","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/978-1-4419-1399-9_52","article-title":"Slit-robo signaling in ocular angiogenesis","volume":"664","author":"Chen","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"10.1016\/j.earlhumdev.2011.05.009_bb0395","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.cellsig.2008.03.002","article-title":"Vascular endothelial growth factor induces heat shock protein (HSP) 27 serine 82 phosphorylation and endothelial tubulogenesis via protein kinase D and independent of p38 kinase","volume":"20","author":"Evans","year":"2008","journal-title":"Cell Signal"},{"issue":"10","key":"10.1016\/j.earlhumdev.2011.05.009_bb0400","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nm.1873","article-title":"The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis","volume":"14","author":"Sapieha","year":"2008","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0405","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10633-009-9181-x","article-title":"The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50\/10 OIR model","volume":"120","author":"Hartnett","year":"2010","journal-title":"Doc Ophthalmol"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.05.009_bb0410","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1167\/iovs.07-1356","article-title":"Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model","volume":"49","author":"Saito","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0415","first-page":"840","article-title":"Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity","volume":"13","author":"Saito","year":"2007","journal-title":"Mol Vis"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.05.009_bb0420","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.exer.2009.12.012","article-title":"Role of Nrf2 in retinal vascular development and the vaso-obliterative phase of oxygen-induced retinopathy","volume":"90","author":"Uno","year":"2010","journal-title":"Exp Eye Res"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.05.009_bb0425","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/j.1471-4159.2009.06081.x","article-title":"Stress-induced activation of Nox contributes to cell survival signalling via production of hydrogen peroxide","volume":"109","author":"Groeger","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.earlhumdev.2011.05.009_bb0430","first-page":"283","article-title":"Rod and cone photoreceptor cells produce ROS in response to stress in a live retinal explant system","volume":"16","author":"Bhatt","year":"2010","journal-title":"Mol Vis"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0435","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1152\/physrev.00044.2005","article-title":"The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology","volume":"87","author":"Bedard","year":"2007","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.05.009_bb0440","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.bcp.2010.05.020","article-title":"Peptide-based inhibitors of the phagocyte NADPH oxidase","volume":"80","author":"El-Benna","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.05.009_bb0445","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1167\/iovs.09-3552","article-title":"Cellular and vascular changes in the retina of neonatal rats after an acute exposure to hypoxia","volume":"50","author":"Kaur","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0450","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10633-009-9201-x","article-title":"Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy","volume":"120","author":"Kermorvant-Duchemin","year":"2010","journal-title":"Doc Ophthalmol"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0455","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jcp.21152","article-title":"Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa","volume":"213","author":"Komeima","year":"2007","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.05.009_bb0460","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1167\/iovs.08-2310","article-title":"Effect of lutein on retinal neurons and oxidative stress in a model of acute retinal ischemia\/reperfusion","volume":"50","author":"Li","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.05.009_bb0465","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3341\/kjo.2010.24.2.108","article-title":"Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy","volume":"24","author":"Kim","year":"2010","journal-title":"Korean J Ophthalmol"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.05.009_bb0470","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/mol.109.061366","article-title":"Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy","volume":"77","author":"DeNiro","year":"2010","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0475","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.109.157941","article-title":"Early intervention of tyrosine nitration prevents vaso-obliteration and neovascularization in ischemic retinopathy","volume":"332","author":"Abdelsaid","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.earlhumdev.2011.05.009_bb0480","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/nm1336","article-title":"Trans-arachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration","volume":"11","author":"Kermorvant-Duchemin","year":"2005","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.earlhumdev.2011.05.009_bb0485","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.arcmed.2007.05.003","article-title":"Interaction between iNOS and COX-2 in hypoxia-induced retinal neovascularization in mice","volume":"38","author":"He","year":"2007","journal-title":"Arch Med Res"},{"issue":"7","key":"10.1016\/j.earlhumdev.2011.05.009_bb0490","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nm1591","article-title":"Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis","volume":"13","author":"Connor","year":"2007","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.05.009_bb0495","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1167\/iovs.06-0407","article-title":"Pathological but not physiological retinal neovascularization is altered in TNF-Rp55-receptor-deficient mice","volume":"47","author":"Kociok","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0500","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1167\/iovs.09-3457","article-title":"Suppression of ICAM-1 in retinal and choroidal endothelial cells by plasmid small-interfering RNAs in vivo","volume":"51","author":"Hirano","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0505","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ydbio.2007.12.008","article-title":"Attenuation of retinal vascular development and neovascularization in PECAM-1-deficient mice","volume":"315","author":"Dimaio","year":"2008","journal-title":"Dev Biol"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.05.009_bb0510","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/bjo.2008.142646","article-title":"Comprehensive gene-expression profile in murine oxygen-induced retinopathy","volume":"93","author":"Sato","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.05.009_bb0515","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1203\/PDR.0b013e3181d01a36","article-title":"NICHD neonatal research network. Perinatal systemic inflammatory response syndrome and retinopathy of prematurity","volume":"67","author":"Sood","year":"2010","journal-title":"Pediatr Res"}],"container-title":["Early Human Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037837821100199X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037837821100199X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T17:39:48Z","timestamp":1592674788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037837821100199X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":103,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S037837821100199X"],"URL":"https:\/\/doi.org\/10.1016\/j.earlhumdev.2011.05.009","relation":{},"ISSN":["0378-3782"],"issn-type":[{"value":"0378-3782","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}